What this band has actually done:
stocks scoring 25–45
beat the S&P 500 over the next three months
45.3%
of the time, across 39,662 cases
since 2015.
That is below a coin flip — and so is every other band, because the
median stock loses to a cap-weighted index.
How we measured this
Hedge funds
46
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$122M
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqCM
About COSTAR GROUP INC
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as…
Who's behind the signal
Every informed buyer we can see on COYA, across all three feeds.
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
COSTAR GROUP INC isn't in the top-10 model right now, but 9 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
9
Investors
1
New positions
5
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to COSTAR GROUP INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell COSTAR GROUP INC or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime
ESC
Type to search across stocks, 50 investors & Congress.